{"entity": "publication", "iuid": "c15f27acb2e04afaac5f6651b209bda6", "timestamp": "2026-08-22T07:48:06.506Z", "links": {"self": {"href": "https://publications-affiliated.scilifelab.se/publication/c15f27acb2e04afaac5f6651b209bda6.json"}, "display": {"href": "https://publications-affiliated.scilifelab.se/publication/c15f27acb2e04afaac5f6651b209bda6"}}, "title": "Concomitant Ro/SSA and La/SSB antibodies are biomarkers for the risk of venous thromboembolism and cerebral infarction in primary Sj\u00f6gren's syndrome.", "authors": [{"family": "Mofors", "given": "J", "initials": "J"}, {"family": "Holmqvist", "given": "M", "initials": "M"}, {"family": "Westermark", "given": "L", "initials": "L"}, {"family": "Bj\u00f6rk", "given": "A", "initials": "A"}, {"family": "Kvarnstr\u00f6m", "given": "M", "initials": "M"}, {"family": "Forsblad-d'Elia", "given": "H", "initials": "H"}, {"family": "Magnusson Bucher", "given": "S", "initials": "S"}, {"family": "Eriksson", "given": "P", "initials": "P"}, {"family": "Theander", "given": "E", "initials": "E"}, {"family": "Mandl", "given": "T", "initials": "T"}, {"family": "Wahren-Herlenius", "given": "M", "initials": "M", "orcid": "0000-0002-0915-7245", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/0db5190dbe894a5e9cd961e66ba5c75d.json"}}, {"family": "Nordmark", "given": "G", "initials": "G", "orcid": "0000-0002-3829-7431", "researcher": {"href": "https://publications-affiliated.scilifelab.se/researcher/f618934952594d76a747bcbe2c27bbf2.json"}}], "type": "journal article", "published": "2019-10-00", "journal": {"title": "J. Intern. Med.", "issn": "1365-2796", "volume": "286", "issue": "4", "pages": "458-468", "issn-l": "0954-6820"}, "abstract": "To assess the risk of incident cardiovascular disease in patients with primary Sj\u00f6gren's syndrome, overall and stratified by Ro/SSA and La/SSB autoantibody status.\n\nA cohort of patients with primary Sj\u00f6gren's syndrome in Sweden (n = 960) and matched controls from the general population (n = 9035) were included, and data extracted from the National Patient Register to identify events of myocardial infarction, cerebral infarction and venous thromboembolism. Hazard ratios were estimated using cox proportional hazard regressions.\n\nDuring a median follow-up of 9.5 years, the overall hazard ratio (HR) was 1.6 (95% CI 1.2-2.1) for myocardial infarction, 1.2 (95% CI 0.9-1.7) for cerebral infarction and 2.1 (95% CI 1.6-2.9) for venous thromboembolism. Patients positive for both Ro/SSA and La/SSB autoantibodies had a substantially higher risk of cerebral infarction (HR 1.7, 95% CI 1.0-2.9) and venous thromboembolism (HR 3.1, 95% CI 1.9-4.8) than the general population. These risks were not significantly increased in Ro/SSA- and La/SSB-negative patients. Among autoantibody-positive patients, the highest HR of cerebral infarction was seen after \u226510 years disease duration (HR 2.8, 95% CI 1.4-5.4), while the HR for venous thromboembolism was highest 0-5 years after disease diagnosis (HR 4.7, 95% CI 2.3-9.3) and remained high throughout disease duration.\n\nPrimary Sj\u00f6gren's syndrome is associated with a markedly increased risk of cardiovascular disease and the presence of Ro/SSA and La/SSB autoantibodies identify the subgroup of patients carrying the highest risk. These findings suggest that monitoring and prevention of cardiovascular disease in this patient group should be considered.", "doi": "10.1111/joim.12941", "pmid": "31127862", "labels": [], "xrefs": [{"db": "pmc", "key": "PMC6851863"}], "notes": [], "created": "2026-08-21T12:20:12.720Z", "modified": "2026-08-21T12:20:12.768Z"}